Devonian Health Group Inc (GSD) - Total Liabilities

Latest as of October 2025: CA$5.97 Million CAD ≈ $4.32 Million USD

Based on the latest financial reports, Devonian Health Group Inc (GSD) has total liabilities worth CA$5.97 Million CAD (≈ $4.32 Million USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GSD operating cash flow to assess how effectively this company generates cash.

Devonian Health Group Inc - Total Liabilities Trend (2015–2025)

This chart illustrates how Devonian Health Group Inc's total liabilities have evolved over time, based on quarterly financial data. Check GSD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Devonian Health Group Inc Competitors by Total Liabilities

The table below lists competitors of Devonian Health Group Inc ranked by their total liabilities.

Company Country Total Liabilities
Khadim India Limited
NSE:KHADIM
India Rs4.10 Billion
Arvee Laboratories (India) Limited
NSE:ARVEE
India Rs91.40 Million
Clean Seas Seafood Ltd
AU:CSS
Australia AU$20.12 Million
OCB Bhd
KLSE:5533
Malaysia RM98.56 Million
Castor Maritime Inc
NASDAQ:CTRM
USA $80.40 Million
Everbright Digital Holding Limited Ordinary Shares
NASDAQ:EDHL
USA $532.65K
Silverline Endustri ve Ticaret AS
IS:SILVR
Turkey TL886.75 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Devonian Health Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Devonian Health Group Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.44 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.62 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Devonian Health Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Devonian Health Group Inc (2015–2025)

The table below shows the annual total liabilities of Devonian Health Group Inc from 2015 to 2025.

Year Total Liabilities Change
2025-07-31 CA$6.69 Million
≈ $4.84 Million
-60.34%
2024-07-31 CA$16.87 Million
≈ $12.21 Million
+242.26%
2023-07-31 CA$4.93 Million
≈ $3.57 Million
-7.22%
2022-07-31 CA$5.31 Million
≈ $3.84 Million
-25.00%
2021-07-31 CA$7.08 Million
≈ $5.12 Million
-3.11%
2020-07-31 CA$7.31 Million
≈ $5.29 Million
+3.41%
2019-07-31 CA$7.07 Million
≈ $5.12 Million
+10.10%
2018-07-31 CA$6.42 Million
≈ $4.65 Million
+90.57%
2017-07-31 CA$3.37 Million
≈ $2.44 Million
-43.33%
2016-07-31 CA$5.95 Million
≈ $4.30 Million
+16718.26%
2016-06-30 CA$35.36K
≈ $25.58K
-99.46%
2015-07-31 CA$6.55 Million
≈ $4.73 Million
--

About Devonian Health Group Inc

V:GSD Canada Biotechnology
Market Cap
$20.01 Million
CA$27.66 Million CAD
Market Cap Rank
#25034 Global
#982 in Canada
Share Price
CA$10.00
Change (1 day)
-15.97%
52-Week Range
CA$0.11 - CA$14.00
All Time High
CA$14.00
About

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more